Amgen's Multiple Myeloma Drug Shows Promise in Phase 3 Trial

Now watching

Next video starts in : 7 Play

Amgen's Multiple Myeloma Drug Shows Promise in Phase 3 Trial

Amgen's Multiple Myeloma Drug Shows Promise in Phase 3 Trial
Replay video
Up next

What to Watch in the Week Ahead: Dollar Tree Earnings, PMI

Unlock your personal NFL Now stream by signing in to NFL.com

Amgen's Multiple Myeloma Drug Shows Promise in Phase 3 Trial

by TheStreet 1:11 mins

Amgen's Multiple Myeloma Drug Shows Promise in Phase 3 Trial

by TheStreet 1:11 mins

Shares of Amgen are moving higher on Monday. The drug maker is seeing great signs in the development of treatment for multiple myeloma, a bone marrow cancer. The results from its Phase 3 of Kyprolis' clinical trial shows that patients can live almost nine months longer without worsening symptoms. According to Amgen, about 70,000 people in the U.S. are living with the disease and 24,000 new cases are diagnosed every year. With the good clinical trial result, Amgen plans to begin regulatory submissions around the world next year. Dr. Pablo Cagnoni, president of Amgen's subsidiary Onyx Pharmaceuticals said, "The results demonstrate that Kyprolis can significantly extend the time patients live without their disease progressing. The ability of novel therapies to produce deep and durable responses may, one day, transform this uniformly fatal disease to one that is chronic and manageable." Male patients over the age of 65 have the highest risk of developing it.

TheStreet

Finance

  1. 1:01

    The Biebs is back: Justin Bieber by the numbers

  2. 1:04

    Yahoo Finance cocktail of the week: The wild ride

  3. 14:54

    Markets calm down, Sprint vs. AT&T and 'sky high' wifi prices

  4. 4:23

    China fears linger as focus on Fed sharpens

  5. 3:34

    China's Wanda buys Ironman Triathlon owner for $650 mln

  6. 2:31

    Sky high wifi prices

Personal Finance

  1. 3:44

    A local man’s view on the real recovery of post-Katrina New Orleans

  2. A local man’s view on the real recovery of post-Katrina New Orleans

  3. 1:40

    How Much Money Do You Need to Be Rich? Kids' Answers Will Inspire You.

  4. 1:34

    Young people and startups are fueling New Orleans’ recovery after Hurricane Katrina

  5. 1:52

    Here's how smart investors will react to today's market drama

  6. 2:33

    In post-Katrina New Orleans, black men lift each other up

Investing

  1. 1:39

    Icahn buys into FCX, big changes at BIG, ULTA looking pretty

  2. 1:52

    Three tests face a market shaken by volatility storm

  3. 1:31

    3 tips for managing money in a volatile market

  4. 3:52

    Analyst trolls Chanos, says he's lying about Elon Musk's SolarCIty

  5. 3:47

    Unhinged market tests Wall Street rules of thumb

  6. 5:03

    No fundamental reason for oil's 'meltdown': energy analyst

Market Movers